Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2024 | $16.00 → $6.50 | Buy → Neutral | UBS |
| 5/8/2024 | $15.00 → $5.50 | Overweight → Equal-Weight | Morgan Stanley |
| 5/8/2024 | $17.00 → $7.00 | Buy → Hold | Truist |
| 5/8/2024 | $15.00 → $6.00 | Buy → Hold | Stifel |
| 5/8/2024 | $15.00 → $8.00 | Overweight → Neutral | JP Morgan |
| 5/8/2024 | Buy → Neutral | BTIG Research | |
| 9/29/2023 | $24.00 | Buy | UBS |
| 5/1/2023 | $33.00 | Buy | Truist |
SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
Treace Medical Concepts (NASDAQ:TMCI) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 7 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 5 0 0 Analysts have set 12-month price targets for Treace Medical Concepts, revealing an average target of $8.25, a high estimate of $16.00, and a low estimate of $5.50. Observing a downward trend,
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $7 to $9.
Morgan Stanley analyst Drew Ranieri maintains Treace Medical Concepts (NASDAQ:TMCI) with a Equal-Weight and raises the price target from $5.5 to $8.
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, beginning at approximately 8:00 am ET. A live webcast and replay of the fireside chat will be available on the Company's investors relations website at https://inve
PONTE VEDRA, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue of $45.1 million in third quarter 2024 increased 11% over same period in 2023Third quarter 2024 net loss was ($15.4) million compared to ($17.5) million for same period in 2023. Adjusted EBITDA loss improved 45% to ($5.1) million in the third quarter 2024 compared to ($9.2
PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 11:45 am ET. A live webcast and replay of the fireside chat will be available on the Company's investors relations website at https://investor
PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 5, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in nu
PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbe
PONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Tuesday, May 7, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in number
10-Q - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
UBS downgraded Treace Medical Concepts from Buy to Neutral and set a new price target of $6.50 from $16.00 previously
Morgan Stanley downgraded Treace Medical Concepts from Overweight to Equal-Weight and set a new price target of $5.50 from $15.00 previously
Truist downgraded Treace Medical Concepts from Buy to Hold and set a new price target of $7.00 from $17.00 previously
PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts. "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou
PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit
PONTE VEDRA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced the appointment of Lance E. Berry and Jane E. Kiernan to its board of directors, effective October 1, 2022. "With decades of combined experience leading medical device companies, Lance and Jane strengthen the expertise of our Company's board of directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board look forward to their support and guidance through our next phase of grow
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)